EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Outcomes and treatment patterns in germline BRCA1/2 carriers from two matched cohort studies

Stefania Morganti iD, Se E Kim, Qingchun Jin iD, Jaeyoon Cha iD, Jacqueline E Zeigler, Alexandra B Newman iD, Gregory J Kirkner iD, Craig Snow iD, Yue Zheng iD, Julie Vincuilla, Tonia Parker iD, Ryan M Buehler iD und 24 weitere

JNCI Cancer Spectrum · 07.07.2026 · 10 (4)

DOI: 10.1093/jncics/pkag055 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JNCI Cancer Spectrum, online erschienen am 25.05.2026. Verfasst von Stefania Morganti und 35 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States. Hauptthemen laut MEDLINE: Germ-Line Mutation, Breast Neoplasms, Heterozygote, Genes, BRCA1. Die Arbeit nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: METAvivor, Breast Cancer Research Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Whether outcomes of germline BRCA1/2 (gBRCA1/2)-associated breast cancer differ compared with sporadic tumors is controversial. We explored the impact of gBRCA1/2 pathogenic variant (PV) status beyond established prognostic features.

Methods

We conducted 2 retrospective, matched cohort studies comparing gBRCA1/2 PV carriers and noncarriers with HER2-negative, stage I-III breast cancer (Clinical Outcomes Quality Database [COQD] cohort: 185 carriers, 555 noncarriers; Young Women’s Breast Cancer Study [YWS] cohort: 113 carriers, 226 noncarriers). Matching factors were age, stage, hormone receptor status, and year of diagnosis. Clinicopathological features, treatments, and survival outcomes were compared between carriers and noncarriers.

Results

Most patients in COQD had stage I-II disease (87.2%), and more carriers than noncarriers had genetic testing before diagnosis (33% vs 5.6%, P < .001). In YWS, 22.7% of patients had stage III tumors, and few were tested before diagnosis (14.8% of carriers vs 1.7% of noncarriers; P < .001). Carriers in COQD received chemotherapy more often than noncarriers (81.1 vs 67.0%, P < .001), including platinum (P = .010); the proportion was similar for carriers and noncarriers in YWS. After adjusting for chemotherapy, relapse-free survival was longer in carriers than noncarriers in COQD (adjusted hazard ratio = 0.48 [95% CI = 0.26 to 0.87], P = .016), and a favorable trend was observed for other survival outcomes in both cohorts. Triple-negative tumors appeared to drive the differences.

Conclusions

We observed a trend toward improved outcomes in gBRCA1/2 PV carriers compared with noncarriers. These findings suggest that carriers should not receive more aggressive treatment solely based on their germline mutation status. Prospective clinical trials in this population are warranted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Germ-Line MutationBreast NeoplasmsHeterozygoteGenes, BRCA1Genes, BRCA2HumansFemaleRetrospective StudiesMiddle AgedAdultGenetic TestingNeoplasm StagingTreatment OutcomeDisease-Free SurvivalAgedErb-b2 Receptor Tyrosine Kinases

Substanzen

Erb-b2 Receptor Tyrosine Kinases

Autor:innen und Institutionen

  • Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, United States.
  • Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, United States.
  • Harvard Medical School, Boston, MA, United States.
  • Broad Institute of MIT and Harvard, Cambridge, MA, United States.
  • Data Science, Dana-Farber Cancer Institute, Boston, MA, United States.
  • Department of Medicine, Brigham and Women's Hospital, Boston, MA, United States.

ORCID-Profile: Stefania Morganti, Qingchun Jin, Jaeyoon Cha, Alexandra B Newman, Gregory J Kirkner, Craig Snow, Yue Zheng, Tonia Parker, Ryan M Buehler, Brittany L Bychkovsky, Kate E Dibble, Tal Sella, Kathryn J Ruddy, Jeffrey Peppercorn, Virginia F Borges, Yaileen D Guzman-Arocho, Steven E Come, Philip D Poorvu, Matteo Lambertini, Giuseppe Curigliano, Elizabeth A Mittendorf, Tari A King, Nancy U Lin, Judy E Garber, Nabihah Tayob, Sara M Tolaney, Ann H Partridge, Filipa Lynce

Förderung

  • METAvivor
  • Breast Cancer Research Foundation

Zitieren

APA

Morganti, S., Kim, S. E., Jin, Q., Cha, J., Zeigler, J. E., Newman, A. B., Kirkner, G. J., Snow, C., Zheng, Y., Vincuilla, J., Parker, T., Buehler, R. M., Bychkovsky, B. L., Dibble, K. E., Sella, T., Ruddy, K. J., Rosenberg, S. M., Collins, L. C., Peppercorn, J., …, & Lynce, F. (2026). Outcomes and treatment patterns in germline BRCA1/2 carriers from two matched cohort studies. JNCI Cancer Spectrum, 10(4). https://doi.org/10.1093/jncics/pkag055

Vancouver

Morganti S, Kim SE, Jin Q, Cha J, Zeigler JE, Newman AB, et al. Outcomes and treatment patterns in germline BRCA1/2 carriers from two matched cohort studies. JNCI Cancer Spectrum. 2026;10(4). doi:10.1093/jncics/pkag055

BibTeX
@article{Morganti2026,
  author = {Morganti, Stefania and Kim, Se E and Jin, Qingchun and Cha, Jaeyoon and Zeigler, Jacqueline E and Newman, Alexandra B and Kirkner, Gregory J and Snow, Craig and Zheng, Yue and Vincuilla, Julie and Parker, Tonia and Buehler, Ryan M and Bychkovsky, Brittany L and Dibble, Kate E and Sella, Tal and Ruddy, Kathryn J and Rosenberg, Shoshana M and Collins, Laura C and Peppercorn, Jeffrey and Schapira, Lidia and Borges, Virginia F and Guzman-Arocho, Yaileen D and Come, Steven E and Warner, Ellen and Poorvu, Philip D and Lambertini, Matteo and Curigliano, Giuseppe and Hughes, Melissa E and Mittendorf, Elizabeth A and King, Tari A and Lin, Nancy U and Garber, Judy E and Tayob, Nabihah and Tolaney, Sara M and Partridge, Ann H and Lynce, Filipa},
  title = {Outcomes and treatment patterns in germline BRCA1/2 carriers from two matched cohort studies},
  journal = {JNCI Cancer Spectrum},
  year = {2026},
  volume = {10},
  number = {4},
  doi = {10.1093/jncics/pkag055}
}
Kostenlos starten →